Nemo‑like kinase expression predicts poor survival in colorectal cancer

Chen,Jingbo; Han,Yunwei; Zhao,Xiaoqian; Yang,Mingyu; Liu,Bo; Xi,Xiangpeng; Xu,Xiaolin; Liang,Tiejun; Xia,Lijian

doi:10.3892/mmr.2014.2851

Nemo‑like kinase expression predicts poor survival in colorectal cancer

Authors:
- Jingbo Chen
- Yunwei Han
- Xiaoqian Zhao
- Mingyu Yang
- Bo Liu
- Xiangpeng Xi
- Xiaolin Xu
- Tiejun Liang
- Lijian Xia
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Qianfoshan Hospital of Shandong Province, Jinan, Shandong 250100, P.R. China, School of Medicine, Shandong University, Jinan, Shandong 250100, P.R. China, Department of Digestive Diseases, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: November 3, 2014 https://doi.org/10.3892/mmr.2014.2851
Pages: 1181-1187

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nemo‑like kinase (NLK), a serine/threonine protein kinase, was previously reported to be associated with tumor proliferation and invasion. The present study aimed to evaluate whether NLK participates in the tumorigenesis and progression of colorectal cancer (CRC). NLK expression was examined using reverse transcription quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis in 50 paired CRC tissues as well as immunohistochemical analysis of 406 cases of primary CRC tissues and paired non‑cancerous tissues. Correlations between NLK expression, the clinicopathological features of CRC patients and clinical outcome were then analyzed. NLK expression was found to be significantly higher in CRC tissues as well as associated with the depth of tumor invasion, lymph node metastasis, distant metastasis, histological differentiation, vascular invasion and advanced tumor stage. Patients with NLK‑positive tumors demonstrated higher rates of recurrence and mortality than patients with NLK‑negative tumors. Multivariate analyses revealed that NLK expression was an independent factor for overall survival [hazard ratio (HR)=0.035; 95% confidence interval (CI)=0.02‑0.19; P<0.001] and disease‑free survival (HR=0.033; 95% CI=0.007‑0.09; P<0.001) in CRC patients. In conclusion, the results of the present study indicated that NLK may serve as a novel biomarker for tumor recurrence and survival for CRC patients.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Gaedcke J, Grade M, Camps J, Søkilde R, Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi BM, Møller S, et al: The rectal cancer microRNAome - microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res. 18:4919–4930. 2012. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
4	Zhang S, Cui Y, Weng Z, Gong X, Chen M and Zhong B: Changes on the disease pattern of primary colorectal cancers in Southern China: a retrospective study of 20 years. Int J Colorectal Dis. 24:943–949. 2009. View Article : Google Scholar : PubMed/NCBI
5	Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
6	Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ and van der Burg SH: Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines. 10:899–921. 2011. View Article : Google Scholar : PubMed/NCBI
7	Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO and Lothe RA: Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients. J Clin Oncol. 21:820–829. 2003. View Article : Google Scholar : PubMed/NCBI
8	Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009. View Article : Google Scholar : PubMed/NCBI
9	Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28:466–474. 2010. View Article : Google Scholar
10	Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 418:9342002. View Article : Google Scholar : PubMed/NCBI
11	French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE and Thibodeau SN: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 14:3408–3415. 2008. View Article : Google Scholar : PubMed/NCBI
12	Anastas JN and Moon RT: WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 13:11–26. 2013. View Article : Google Scholar
13	Ishikawa T, Shimizu D, Kito A, Ota I, Sasaki T, Tanabe M, Yamada A, Arioka H, Shimizu S, Wakasugi J, et al: Breast cancer manifested by hematologic disorders. J Thorac Dis. 4:650–654. 2012.PubMed/NCBI
14	Emami KH, Brown LG, Pitts TE, Sun X, Vessella RL and Corey E: Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate. 69:1481–1492. 2009. View Article : Google Scholar : PubMed/NCBI
15	Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ, Xie HJ, Ahn YM, Park WS, Lee JY and Nam SW: Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem. 110:687–696. 2010. View Article : Google Scholar : PubMed/NCBI
16	Cui G, Li Z, Shao B, Zhao L, Zhou Y, Lu T, Wang J, Shi X, Wang J, Zuo G, et al: Clinical and biological significance of nemo-like kinase expression in glioma. J Clin Neurosci. 18:271–275. 2011. View Article : Google Scholar
17	Wang S, Wu X, Chen Y, Zhang J, Ding J, Zhou Y, He S, Tan Y, Qiang F, Bai J, et al: Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res. 18:2987–2996. 2012. View Article : Google Scholar : PubMed/NCBI
18	Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C and Röcken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 9:139–148. 2008. View Article : Google Scholar : PubMed/NCBI
19	Ishitani T and Ishitani S: Nemo-like kinase, a multifaceted cell signaling regulator. Cell Signal. 25:190–197. 2013. View Article : Google Scholar
20	Ota S, Ishitani S, Shimizu N, Matsumoto K, Itoh M and Ishitani T: NLK positively regulates Wnt/β-catenin signalling by phosphorylating LEF1 in neural progenitor cells. EMBO J. 31:1904–1915. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ishitani T: Context-dependent dual and opposite roles of nemo-like kinase in the Wnt/β-catenin signaling. Cell Cycle. 11:1743–1745. 2012. View Article : Google Scholar : PubMed/NCBI
22	Yasuda J, Yokoo H, Yamada T, Kitabayashi I, Sekiya T and Ichikawa H: Nemo-like kinase suppresses a wide range of transcription factors, including nuclear factor-κB. Cancer Sci. 95:52–57. 2004. View Article : Google Scholar : PubMed/NCBI
23	Li M, Zhang S, Wang Z, Zhang B, Wu X, Weng H, Ding Q, Tan Z, Zhang N, Mu J, et al: Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour Biol. 34:3995–4000. 2013. View Article : Google Scholar : PubMed/NCBI